Ozempic is traditionally used as a treatment for type 2 diabetes (T2DM) to help patients manage blood sugar levels. However, ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Global growth is projected at 3.3 percent both in 2025 and 2026, below the historical (2000–19) average of 3.7 percent. The forecast for 2025 is broadly unchanged from that in the October 2024 World ...

With a market capitalization of $348 billion and strong revenue growth of 26% over the last twelve months, Novo Nordisk remains a dominant force in the pharmaceutical industry. According to ...

With a market capitalization of $348 billion and strong revenue growth of 26% over the last twelve months, Novo Nordisk remains a dominant force in the pharmaceutical industry. According to ...

It's still investing billions in spinning up new manufacturing facilities to ensure that supply capacity stops being a constraint on growth. What's more, Novo Nordisk is in exactly the same ...

and human growth hormone. While Novo Nordisk has built itself into a pharmaceutical giant, it has seriously run afoul of regulatory laws on several occasions. Novo Nordisk’s practices have ...

Semaglutide mimics the naturally occurring GLP-1 hormone by keeping ... for Ozempic is $968.52 per pen without insurance. While this drug can be expensive, Novo Nordisk offers a savings card ...